Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2B dose-ranging study of GSK1278863 vs recombinant human erythropoietin in hemodialysis-dependent CKD anemia
2013-002682-19Phase 2Completed
- Sponsor
- GSK
- Start
- Oct 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of daprodustat in anaemia and chronic kidney disease (CKD) (2 arms), sponsored by GSK. Primary endpoint: Hemoglobin change from baseline at Week 4. Started Oct 2013; status: completed.
02
Drugs
daprodustat
03
Conditions
anaemiachronic kidney disease (CKD)
Beyond the preview
Go deeper on 2013-002682-19.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-002682-19.